BIO 2026: AI and Federal Policy Dominate Global Biotech Agenda

References

1. 1.Hogan, A., Keshavan, M., Trang, B., & Payne, D. (2026). BIO 2026: AI, federal policy impacts, and general vibes. STAT News. https://www.statnews.com/2026/06/26/bio-2026-san-diego-key-takeaways-status-report-alex-hogan/
2. 2.Wouters, O. J., McKee, M., & Luyten, J. (2020). Estimated research and development investment needed to bring a new medicine to market, 2009–2018. JAMA, 323(9), 844–853. https://doi.org/10.1001/jama.2020.1166
3. 3.Kesselheim, A. S., Avorn, J., & Sarpatwari, A. (2016). The high cost of prescription drugs in the United States: origins and prospects for reform. JAMA, 316(8), 858–871. https://doi.org/10.1001/jama.2016.11237
4. 4.Prasad, V., & Mailankody, S. (2017). Research and development spending to bring a single cancer drug to market and revenues after approval. JAMA Internal Medicine, 177(11), 1569–1575. https://doi.org/10.1001/jamainternmed.2017.3601
5. 5.Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., & Hassabis, D. (2021). Highly accurate protein structure prediction with AlphaFold. Nature, 596(7873), 583–589. https://doi.org/10.1038/s41586-021-03819-2
6. 6.Vamathevan, J., Clark, D., Czodrowski, P., Dunham, I., Ferran, E., Lee, G., & Zhao, S. (2019). Applications of machine learning in drug discovery and development. Nature Reviews Drug Discovery, 18(6), 463–477. https://doi.org/10.1038/s41573-019-0024-5
7. 7.Sarpatwari, A., Sinha, M. S., & Kesselheim, A. S. (2019). Reforming the market exclusivity system for pharmaceuticals. PLOS Medicine, 16(8), e1002875. https://doi.org/10.1371/journal.pmed.1002875
8. 8.Vitry, A., & Roughead, E. (2014). Managed entry agreements for pharmaceuticals in Australia. Health Policy, 117(3), 345–352. https://doi.org/10.1016/j.healthpol.2014.02.011